Shares of biotech company Biogen (NASDAQ:BIIB)
fell 3% in the afternoon session after Needham analyst Ami Fadia reiterated a "Hold" rating on the stock. This rating suggests the analyst expects the stock to perform in line with the broader market, lacking a significant catalyst for a major move in either direction. The reiterated neutral stance comes with no change to the price target. The market's negative reaction may indicate that some investors were anticipating a more positive outlook or an upgrade for the biotechnology company.
Wall Street kicked off September on shaky ground as rising bond yields pressured tech stocks and legal turmoil over Trump’s tariffs added fresh uncertainty. Meanwhile, investors brace for Friday’s key jobs report that could steer the Fed's next move.
Shares of biotech company Biogen (NASDAQ:BIIB)
jumped 4.8% in the afternoon session after the company and its partner Eisai received FDA approval for a weekly subcutaneous injection of their Alzheimer's drug, Leqembi, for maintenance dosing.
Wall Street stumbled on Tuesday, with broad losses by midday in New York as investors turned risk-off amid mounting concerns over lofty valuations, seasonal headwinds and fiscal strains.
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with Moderna (NASDAQ:MRNA).
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
